Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT
- PMID: 18082989
- DOI: 10.1016/j.ejrad.2007.10.021
Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT
Abstract
Purpose: To compare the diagnostic accuracy for the detection of tumor recurrence in breast cancer patients using whole-body-MRI (WB-MRI) at 1.5 or 3T compared to FDG-PET-CT.
Materials and methods: Thirty-three female patients with breast cancer and suspicion of recurrence underwent FDG-PET-CT and WB-MRI. Coronal T1w-TSE- and STIR-sequences, HASTE-imaging of the lungs, contrast-enhanced T1w- and T2w-TSE-sequences of the liver, brain and abdomen were performed, using a WB-MRI-scanner at 1.5 (n=23) or 3T (n=10). Presence of local recurrence, lymph node involvement and distant metastatic disease was assessed using clinical and radiological follow-up as a standard of reference.
Results: Tumor recurrence was found in 20 of 33 patients. Overall 186 malignant foci were detected with WB-MRI and PET-CT. Both modalities revealed two recurrent tumors of the breast. PET-CT detected more lymph node metastases (n=21) than WB-MRI (n=16). WB-MRI was more precise in the detection of distant metastases (n=154 versus n=147). Sensitivity was 93% (172/186) and 91% (170/186) for WB-MRI and PET-CT, specificity was 86% (66/77) and 90% (69/77), respectively. Examination times for WB-MRI at 1.5 and 3T were 51 and 43 min, respectively, examination time for PET-CT was 103 min.
Conclusion: WB-MRI and PET-CT are useful for the detection of tumor recurrence in the follow-up of breast cancer. WB-MRI is highly sensitive to distant metastatic disease. PET-CT is more sensitive in detecting lymph node involvement. Tumor screening with WB-MRI is feasible at 1.5 and 3T, scan time is further reduced at 3T with identical resolution.
Similar articles
-
Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.Eur Radiol. 2009 Jun;19(6):1366-78. doi: 10.1007/s00330-008-1289-y. Epub 2009 Feb 4. Eur Radiol. 2009. PMID: 19190917
-
Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.Abdom Imaging. 2008 Nov-Dec;33(6):676-88. doi: 10.1007/s00261-007-9347-5. Abdom Imaging. 2008. PMID: 18373114 Clinical Trial.
-
High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.Invest Radiol. 2005 Dec;40(12):743-53. doi: 10.1097/01.rli.0000185878.61270.b0. Invest Radiol. 2005. PMID: 16304476 Clinical Trial.
-
Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.Top Magn Reson Imaging. 2007 Jun;18(3):193-202. doi: 10.1097/RMR.0b013e318093e6bo. Top Magn Reson Imaging. 2007. PMID: 17762383 Review.
-
Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.Q J Nucl Med Mol Imaging. 2013 Dec;57(4):352-66. Q J Nucl Med Mol Imaging. 2013. PMID: 24322792 Review.
Cited by
-
Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.Radiographics. 2019 Jul-Aug;39(4):998-1016. doi: 10.1148/rg.2019180178. Epub 2019 Jun 14. Radiographics. 2019. PMID: 31199711 Free PMC article. Review.
-
Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.Front Oncol. 2021 Nov 19;11:772530. doi: 10.3389/fonc.2021.772530. eCollection 2021. Front Oncol. 2021. PMID: 34869009 Free PMC article. Review.
-
The role of MRI in musculoskeletal practice: a clinical perspective.J Man Manip Ther. 2011 Aug;19(3):152-61. doi: 10.1179/2042618611Y.0000000009. J Man Manip Ther. 2011. PMID: 22851878 Free PMC article.
-
Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo.Biomed Pharmacother. 2017 May;89:146-151. doi: 10.1016/j.biopha.2017.02.003. Epub 2017 Mar 24. Biomed Pharmacother. 2017. PMID: 28222395 Free PMC article.
-
PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.J Clin Med. 2024 Jun 13;13(12):3459. doi: 10.3390/jcm13123459. J Clin Med. 2024. PMID: 38929989 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical